Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.

ABSTRACT:

SUBMITTER: Chevallier P 

PROVIDER: S-EPMC5477620 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature